Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Allergan

Status: Completed

Conditions: Eyelash Hypotrichosis

Treatments: Drug: Bimatoprost cutaneous solution 0.03%

Study type: Observational

Funder types: Industry

Identifiers

NCT02505776

192024-089

Details and patient eligibility

About

This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.

Enrollment: 1,699 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients who have been prescribed GLASH VISTA™ in clinical settings and filled at least one prescription for GLASH VISTA™.

Exclusion criteria

-None.

Trial design

1,699 participants in 1 patient group

GLASH VISTA™

Description:

Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.

Treatment:

Drug: Bimatoprost cutaneous solution 0.03%